| Document |
Document Title |
|
WO/2022/165000A1 |
Provided herein are methods and corresponding compounds for treating fibrotic disease by administering to a subject a compound of Formula I or pharmaceutically acceptable salt thereof, which inhibits phosphorylation of Smad2/3, according...
|
|
WO/2022/160138A1 |
The present invention relates to a benzoxazine-4-one compound represented by formula (I) that acts as a glycogen phosphorylase inhibitor, a preparation method therefor, and a use thereof in a drug for the treatment and/or prevention of d...
|
|
WO/2022/161462A1 |
A substituted morpholine derivative with a structure as shown in a formula (I). In addition, further disclosed are a pharmaceutically acceptable salt, a stereoisomer, a pharmaceutical composition and the use of the derivative.
|
|
WO/2022/157390A1 |
According to the invention there is provided an antimicrobial agent for use in maintaining or re-establishing a healthy genital microbiome, wherein the antimicrobial agent is a predatory bacterium.
|
|
WO/2022/159382A1 |
The subject method described herein relates to a method of treating, preventing, or reducing the incidence of Acute Kidney Injury (AKI) in a subject in need thereof by administering to the subject a pharmaceutically effective amount of o...
|
|
WO/2022/159590A1 |
IL-2 agents that comprise IL-2 variants are disclosed as well as methods, compositions, and uses thereof. The IL-2 agents described herein can be used to treat and/or prevent various disorders and conditions.
|
|
WO/2022/159566A1 |
Methods and compositions for treating organ fibrosis are disclosed. The methods involve administering a genus of benzenesulfonamides, particularly N-[3-(aminosulfonyl)phenyl]-benzamides and heteroarylamides. A genus of suitable compounds...
|
|
WO/2022/156449A1 |
The present invention relates to a novel benzoazepine compound, comprising a pharmaceutically acceptable salt thereof. The present invention also provides a pharmaceutical composition comprising the compound and pharmaceutically acceptab...
|
|
WO/2022/155716A1 |
The present invention pertains to the fields of pharmaceutics, medicine, biotechnology and immunology. More specifically, the present invention describes the use of a compound or of a combination of compounds for preparing a pharmaceutic...
|
|
WO/2022/158956A1 |
The present invention relates to a peptide for preventing or treating fibrosis, having the effects of preventing or treating fibrosis by having the property of inhibiting the dissociation of TGF-β1 from LCC by binding to an integrin or ...
|
|
WO/2022/153042A1 |
This invention relates to a new method of activating 5' adenosine monophosphate- activated protein kinase (AMPK) to treat certain diseases and disorders using a salt of 4-chloro-N-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazo
l-5-yl]...
|
|
WO/2022/153166A1 |
Polypeptides comprising a FimH lectin domain comprising at least one an amino acid mutation that causes the FimH lectin domain to be in the low affinity conformation for mannose are described. Pharmaceutical compositions which comprise s...
|
|
WO/2022/151790A1 |
A Bifidobacterium longum dietary combination for intervening with chronic nephritis and uremia, and the use thereof. The Bifidobacterium longum dietary combination comprises 100 mL of Bifidobacterium longum BL-G301 probiotic milk and 40 ...
|
|
WO/2022/152773A1 |
The present invention relates to a method for treating chronic kidney diseases.
|
|
WO/2022/153261A1 |
Provided are methods for treating a bladder condition in a subject in need thereof by administering to said subject a therapeutically effective dose of a composition comprising at least one cannabinoid and a carrier. Also provided are ca...
|
|
WO/2022/155303A1 |
This invention relates to methods of treating and/or preventing cardiovascular diseases and conditions and to methods of reducing the risk of cardiovascular death, reducing the risk of hospitalization for heart failure, reducing the risk...
|
|
WO/2022/155435A1 |
This document relates to methods and materials for treating a mammal (e.g., a human) having, or at risk of developing, a polycystic disease (e.g., a polycystic kidney disease (PKD)). For example, methods and materials that can be used to...
|
|
WO/2022/151978A1 |
Provided in the present invention is a pharmaceutically active ingredient extract extracted from Polygala japonica Houtt., which extract comprises a flavonol compound of the following formula (I) structure as a first active ingredient, a...
|
|
WO/2022/155614A1 |
Disclosed herein are compounds of Formula (I-A), wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxidant ...
|
|
WO/2022/155674A1 |
The present disclosure relates to compounds, and to their pharmaceutical compositions, that inhibit dipeptidyl peptidase IV (DPP4). Hie compounds selectively promote the proliferation of alveolar type 2 cells (AEC2s) and are useful in th...
|
|
WO/2022/154444A1 |
The present invention relates to a composition including decursinol as an active ingredient for preventing or treating angina, arteriosclerosis, cerebral infarction, and hypertension. Poorly soluble decursinol was found to improve angina...
|
|
WO/2022/147962A1 |
The present invention relates to the field of hemodialysis, in particular to a fat emulsion dialysate, and a preparation method therefor and the use thereof. Provided in the present invention is a fat emulsion dialysate, comprising long-...
|
|
WO/2022/150461A1 |
The present disclosure relates to methods of treating a ciliopathy, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound or pharmaceutical composition thereof, wherein the comp...
|
|
WO/2022/148403A1 |
Provided in the present invention is the use of an inhibitor targeting IL-17C in the treatment of inflammation-associated chronic kidney diseases. It is found for the first time in the present invention that interleukin17C (IL-17C) is a ...
|
|
WO/2022/143893A1 |
The present application relates to a bladder perfusion pharmaceutical composition, comprising an immunological adjuvant or a soluble salt thereof, and a chemical drug capable of causing immunogenic cell death. When the immunological adju...
|
|
WO/2022/143845A1 |
Disclosed are a nitrogen-containing bridged heterocyclic compound, a preparation method therefor, and a medical application thereof. Specifically, disclosed are a nitrogen-containing bridged heterocyclic compound represented by general f...
|
|
WO/2022/143897A1 |
The present invention provides a polymorphic substance of a A-decarburization-5α androstane compound (ACP-2), an application thereof and a preparation method therefor. Specifically, the present invention relates to a polymorphic substan...
|
|
WO/2022/146061A1 |
Provided is a pharmaceutical composition comprising as active ingredients: 5mg of tadalafil or a pharmaceutically acceptable salt thereof; and 0.5 mg of dutasteride or a pharmaceutically acceptable salt thereof, wherein the dissolution r...
|
|
WO/2022/145656A1 |
The present invention relates to a composition for preventing, ameliorating, or treating eye diseases, the composition containing Micrococcus luteus-derived vesicles as an active ingredient. The present inventors have confirmed that when...
|
|
WO/2022/145680A1 |
The present invention relates to extracellular vesicles derived from Micrococcus luteus and use thereof and, in particular, to a composition and the like for ameliorating, preventing or treating neutrophilic pulmonary disease, comprising...
|
|
WO/2022/145443A1 |
The purpose of the present invention is to establish a means for treating chronic kidney diseases including Alport's syndrome. The present invention provides a pharmaceutical composition characterized by containing: a) a renin/angiotensi...
|
|
WO/2022/143940A1 |
A series of piperidine-substituted benzoic acid compounds and the use thereof, and specifically disclosed is a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/145710A1 |
The present invention relates to extracellular vesicles derived from Micrococcus luteus, and a use thereof and, more specifically, to a composition and the like for alleviating, preventing, or treating neurodevelopmental, neurological or...
|
|
WO/2022/146614A1 |
Among the various aspects of the present disclosure is the provision of a method of treating or preventing kidney disease in a subject in need thereof. Another aspect of the present disclosure provides for a method of reducing a number o...
|
|
WO/2022/145711A1 |
The present invention relates to Micrococcus luteus-derived extracellular vesicles and use thereof and, more specifically, a composition comprising Micrococcus luteus-derived extracellular vesicles as an active ingredient for alleviation...
|
|
WO/2022/135322A1 |
A nanocomposite containing a hydrophobic substance and a preparation method therefor, wherein the nanocomposite comprises an emulsion layer, which is obtained by means of emulsifying a hydrophobic substance, such as botulinum toxin, and ...
|
|
WO/2022/138257A1 |
The present invention provides a new substance having a PDE5 inhibitory effect. This PDE5 inhibitor includes a pupae powder or an extract thereof.
|
|
WO/2022/138792A1 |
The purpose of the present invention is to provide a suitable form for a compound, and an active pharmaceutical ingredient thereof, for the prevention and/or treatment of a disease associated with the activation of an EP2 receptor, said ...
|
|
WO/2022/133551A1 |
The present application is directed towards compounds, pharmaceutically acceptable salts or prodrugs thereof, which are inhibitors of Histone Deacetylase (HDAC) binding or function. The compounds especially may have some selectivity for ...
|
|
WO/2022/138791A1 |
The purpose of the present invention is to provide a medicine for the prevention and/or treatment of a disease caused by activation of an EP2 receptor, said medicine containing, as an active ingredient, a compound having an antagonistic ...
|
|
WO/2022/140654A1 |
The present disclosure relates to compositions and methods related to bicyclo[2.2.1] heptanamine-containing compounds and salts thereof.
|
|
WO/2022/140180A1 |
Provided herein are methods for treating kidney disease comprising administering a therapeutic peptide alone or together with one or more agents. Provided herein are methods for reducing kidney damage.
|
|
WO/2022/138258A1 |
The present invention provides a new substance having a PDE5 inhibitory effect. This PDE5 inhibitor includes Paecilomyces tenuipes powder or an extract thereof.
|
|
WO/2022/135523A1 |
Disclosed in the present invention is an application of a BMP4 protein in preparation of a drug for treating or preventing a fibroproliferative disease of an object, wherein the BMP4 protein is a free BMP4 protein or a recombinant vector...
|
|
WO/2022/135534A1 |
A novel substituted nitrogen-containing bicyclic compound and a pharmaceutical composition containing the compound, capable of being used as chymase inhibitors. Also provided are methods for preparing the compound and pharmaceutical comp...
|
|
WO/2022/136486A1 |
The present application discloses compounds of e.g. formulae (2), (1A), (1B) or (1C) as selective atypical chemokine receptor 3 (ACKR3) modulators for the treatment of e.g. cancer, atherosclerotic vascular disease, cardiovascular disease...
|
|
WO/2022/137178A1 |
The present disclosure is directed to a method of treating overactive bladder comprising orally administering to a patient in need thereof a therapeutically effective amount of vibegron, wherein the patient is concomitantly receiving dig...
|
|
WO/2022/140677A1 |
The present disclosure relates to compositions and methods related to bicyclo[2.2.1] heptanamine-containing compounds and salts.
|
|
WO/2022/132066A1 |
The present invention relates to a homogenous pharmaceutical composition comprising propiverine or a pharmaceutically acceptable salt thereof wherein the composition is in an oral solid dosage form with improved pharmaceutical properties.
|
|
WO/2022/129618A1 |
A method for preparing at least one watercress extract, which method comprises: (a) macerating watercress to form an aqueous watercress intermediate; (b) heating at least part of the aqueous watercress intermediate to coagulate at least ...
|
